Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Zydus Lifesciences Limited ( (IN:ZYDUSLIFE) ) has shared an update.
Zydus Lifesciences Ltd., through its subsidiary Zydus Lifesciences Global FZE, has entered into an exclusive licensing and supply agreement with Synthon BV for the generic version of Ozanimod Capsules, targeting the U.S. market. This collaboration allows Zydus to commercialize the product in the U.S., while Synthon will handle regulatory approval and manufacturing. The agreement positions Zydus to enhance its presence in the U.S. pharmaceutical market, particularly in the treatment of multiple sclerosis and ulcerative colitis, and reflects its strategic focus on expanding access to essential medicines.
More about Zydus Lifesciences Limited
Zydus Lifesciences Ltd. is a global innovation-driven healthcare company that focuses on advancing care in therapeutic areas and making essential medicines more accessible to patients. The company operates in the pharmaceutical industry, providing a range of healthcare products and services.
Average Trading Volume: 52,391
Technical Sentiment Signal: Strong Buy
Current Market Cap: 1002.4B INR
See more data about ZYDUSLIFE stock on TipRanks’ Stock Analysis page.